Literature DB >> 27139482

Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.

Guillermo Martín-Gutiérrez1, Jerónimo Rodríguez-Beltrán2, José Manuel Rodríguez-Martínez3, Coloma Costas2, Javier Aznar1, Álvaro Pascual4, Jesús Blázquez5.   

Abstract

Escherichia coli isolates carrying chromosomally encoded low-level-quinolone-resistant (LLQR) determinants are frequently found in urinary tract infections (UTIs). LLQR mutations are considered the first step in the evolutionary pathway producing high-level fluoroquinolone resistance. Therefore, their evolution and dissemination might influence the outcome of fluoroquinolone treatments of UTI. Previous studies support the notion that low urine pH decreases susceptibility to ciprofloxacin (CIP) in E. coli However, the effect of the urinary tract physiological parameters on the activity of ciprofloxacin against LLQR E. coli strains has received little attention. We have studied the activity of ciprofloxacin under physiological urinary tract conditions against a set of well-characterized isogenic E. coli derivatives carrying the most prevalent chromosomal mutations (ΔmarR, gyrA-S83L, gyrA-D87N, and parC-S80R and some combinations). The results presented here demonstrate that all the LLQR strains studied became resistant to ciprofloxacin (according to CLSI guidelines) under physiological conditions whereas the control strain lacking LLQR mutations did not. Moreover, the survival of some LLQR E. coli variants increased up to 100-fold after challenge with a high concentration of ciprofloxacin under UTI conditions compared to the results seen with Mueller-Hinton broth. These selective conditions could explain the high prevalence of LLQR mutations in E. coli Furthermore, our data strongly suggest that recommended methods for MIC determination produce poor estimations of CIP activity against LLQR E. coli in UTIs.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27139482      PMCID: PMC4914671          DOI: 10.1128/AAC.00602-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Physicochemical properties of antibacterial compounds: implications for drug discovery.

Authors:  Rosemarie O'Shea; Heinz E Moser
Journal:  J Med Chem       Date:  2008-02-09       Impact factor: 7.446

Review 2.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

3.  High-protein diets and renal status in rats.

Authors:  V A Aparicio; E Nebot; R García-del Moral; M Machado-Vílchez; J M Porres; C Sánchez; P Aranda
Journal:  Nutr Hosp       Date:  2013 Jan-Feb       Impact factor: 1.057

4.  Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatment.

Authors:  Joep van den Broek d'Obrenan; Theo J M Verheij; Mattijs E Numans; Alike W van der Velden
Journal:  J Antimicrob Chemother       Date:  2014-02-06       Impact factor: 5.790

5.  Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.

Authors:  H J Zeiler
Journal:  Drugs Exp Clin Res       Date:  1985

6.  Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli.

Authors:  Elena López; Marina Elez; Ivan Matic; Jesús Blázquez
Journal:  Mol Microbiol       Date:  2007-04       Impact factor: 3.501

7.  Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis.

Authors:  Mary Ann Cameron; Naim M Maalouf; Beverley Adams-Huet; Orson W Moe; Khashayar Sakhaee
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

Review 8.  Mechanisms of drug resistance: quinolone resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Ann N Y Acad Sci       Date:  2015-07-17       Impact factor: 5.691

9.  Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli.

Authors:  G G Zhanel; J A Karlowsky; R J Davidson; D J Hoban
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

Review 10.  Emerging mechanisms of fluoroquinolone resistance.

Authors:  D C Hooper
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more
  6 in total

1.  Plasmidic qnr Genes Confer Clinical Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions.

Authors:  Guillermo Martín-Gutiérrez; José Manuel Rodríguez-Martínez; Álvaro Pascual; Jerónimo Rodríguez-Beltrán; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.

Authors:  G Martín-Gutiérrez; F Docobo-Pérez; J Rodriguez-Beltrán; J M Rodríguez-Martínez; J Aznar; A Pascual; J Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Heme cross-feeding can augment Staphylococcus aureus and Enterococcus faecalis dual species biofilms.

Authors:  Jun-Hong Ch'ng; Mugil Muthu; Kelvin K L Chong; Jun Jie Wong; Casandra A Z Tan; Zachary J S Koh; Daniel Lopez; Artur Matysik; Zeus J Nair; Timothy Barkham; Yulan Wang; Kimberly A Kline
Journal:  ISME J       Date:  2022-05-19       Impact factor: 11.217

4.  Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.

Authors:  A Dalhoff; S Schubert; A Vente
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  Recurrent bacteremia with a hypermucoviscous Escherichia coli isolated from a patient with perihilar cholangiocarcinoma: insights from a comprehensive genome-based analysis.

Authors:  Bernd Neumann; Norman Lippmann; Sebastian Wendt; Thomas Karlas; Christoph Lübbert; Guido Werner; Yvonne Pfeifer; Christopher F Schuster
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-06-24       Impact factor: 6.781

6.  Characterization of Plasmid-Mediated Quinolone Resistance and Serogroup Distributions of Uropathogenic Escherichia coli among Iranian Kidney Transplant Patients.

Authors:  Amin Sadeghi; Mehrdad Halaji; Amirhossein Fayyazi; Seyed Asghar Havaei
Journal:  Biomed Res Int       Date:  2020-10-27       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.